WuXi Biologics Reports Solid 2023 Interim Results
Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y Growth,...
Nordrhein Westfalen Hong Kong United States Pharmadule Morimatsu Chris Chen International Society For Pharmaceutical Engineering
Source: prnewswire.com